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Abstract
Background: Recent studies suggest that microglia contribute to tau pathology progression in Alzheimer’s disease.
Amyloid plaque accumulation transforms microglia, the primary innate immune cells in the brain, into
neurodegenerative microglia (MGnD), which exhibit enhanced phagocytosis of plaques, apoptotic neurons and
dystrophic neurites containing aggregated and phosphorylated tau (p-tau). It remains unclear how microglia
promote disease progression while actively phagocytosing pathological proteins, therefore ameliorating pathology.
Methods: Adeno-associated virus expressing P301L tau mutant (AAV-P301L-tau) was stereotaxically injected into
the medial entorhinal cortex (MEC) in C57BL/6 (WT) and humanized APP mutant knock-in homozygote (AppNL-G-F)
mice at 5 months of age. Mice were fed either chow containing a colony stimulating factor-1 receptor inhibitor
(PLX5622) or control chow from 4 to 6 months of age to test the effect of microglia depletion. Animals were tested
at 6 months of age for immunofluorescence, biochemistry, and FACS of microglia. In order to monitor microglial
extracellular vesicle secretion in vivo, a novel lentiviral EV reporter system was engineered to express mEmerald-
CD9 (mE-CD9) specifically in microglia, which was injected into the same region of MEC.
Results: Expressing P301L tau mutant in the MEC induced tau propagation to the granule cell layer of the
hippocampal dentate gyrus, which was significantly exacerbated in AppNL-G-F mice compared to WT control mice.
Administration of PLX5622 depleted nearly all microglia in mouse brains and dramatically reduced propagation of
p-tau in WT and to a greater extent in AppNL-G-F mice, although it increased plaque burden and plaque-associated
p-tau+ dystrophic neurites. Plaque-associated MGnD microglia strongly expressed an EV marker, tumor susceptibility
gene 101, indicative of heightened synthesis of EVs. Intracortical injection of mE-CD9 lentivirus successfully induced
microglia-specific expression of mE-CD9+ EV particles, which were significantly enhanced in Mac2+ MGnD microglia
compared to Mac2− homeostatic microglia. Finally, consecutive intracortical injection of mE-CD9 lentivirus and AAV-
P301L-tau into AppNL-G-F mice revealed encapsulation of p-tau in microglia-specific mE-CD9+ EVs as determined by
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super-resolution microscopy and immuno-electron microscopy.
Discussion: Our findings suggest that MGnD microglia hyper-secrete p-tau+ EVs while compacting Aβ plaques and
clearing NP tau, which we propose as a novel mechanistic link between amyloid plaque deposition and
exacerbation of tau propagation in AppNL-G-F mice.
Keywords: Adeno-associated virus, Alzheimer’s disease, Amyloid-beta peptide, Amyloid precursor protein,
Extracellular vesicles, Humanized mouse model, Lentivirus, Microglia, Microtubule-associated protein tau, Neuritic
plaque, Tauopathy
Background
Microglia are the immune cells of the central nervous
system and possess a number of specific roles including
synaptic pruning [1, 2], release of pro-inflammatory and
anti-inflammatory cytokines [3, 4], as well as surveying
for and phagocytosing pathologic insults [5–7]. Recently,
a class of disease-activated microglia common in neuro-
degeneration called “MGnD” has been characterized
along with their role in the alleviation or exacerbation of
neurodegenerative disorders [8, 9]. MGnD exhibit char-
acteristics similar to activated microglia and possess a
unique molecular signature that is regulated by Trigger-
ing Receptor Expressed on Myeloid cells 2 (TREM2) and
Apolipoprotein E (ApoE), which disrupts maintenance
of central nervous system (CNS) homeostasis [8, 9].
MGnD microglia, which are identified via immunofluor-
escence against markers such as C-type lectin domain
family 7, member A (Clec7A) and galectin-3 (Mac2),
typically reside around amyloid plaques and phagocytose
not only aggregated proteins, but also apoptotic neurons
and synapses. There is still ongoing discussion as to
whether MGnD microglia are ultimately beneficial or
harmful in neurodegenerative disease. MGnD microglia
may play a key role bridging amyloid plaque toxicity and
tau pathology development in Alzheimer’s disease (AD).
Amyloid plaques precede tau pathology in AD and are
believed to initiate or build upon mechanisms respon-
sible for tau pathology. Indeed, previous reports showed
that amyloid-beta (Aβ) pathology accelerates tau path-
ology development in different mouse models [10–12].
Lately, the interplay between the spread of pathologic
hyperphosphorylated tau (p-tau) and Aβ plaques has
been a subject of investigation as p-tau+ aggregates de-
posited on plaques, referred to as “NP tau”, appear to
affect sequestration and spread of pathologic tau seeds
in a manner that may be dependent on microglia [10,
13]. It is still undetermined whether microglia play a
critical role for the acceleration of tau propagation in
the presence of Aβ plaque deposition.
One of the methods in which we can assess the effect
of microglia on AD pathology is through their selective
depletion. This is accomplished in mouse models of con-
ditional knockdown of microglia, targeted depletion, or
via administration of Colony stimulating factor 1 recep-
tor (CSF1R) inhibitors [14–18]. By using CSF1R inhibi-
tors, along with other means of selective microglia
depletion, researchers examined the effect of depletion
on amyloid plaque deposition, tau pathology and spread,
synaptic integrity, as well as cognition in a variety of
mouse models of neurodegeneration [19–23]. We previ-
ously established a rapid tau propagation model in which
AAV-P301L-tau is injected into the medial entorhinal
cortex (MEC) where p-tau is expressed and eventually
propagated to the granular cell layer (GCL) of the
hippocampal dentate gyrus (DG) in a manner facili-
tated by microglia and exosomes, which are small
extracellular vesicles (EVs) synthesized in multivesicu-
lar bodies [22]. In the present study, we investigated
how microglia may facilitate tau propagation by
injecting AAV-P301L-tau into the MEC of C57BL/6
(WT) and AppNL-G-F knock-in mice while treating
them with a CSF1R inhibitor. AppNL-G-F mice develop
robust amyloid plaque formation by endogenously ex-
pressing three APP mutations [24].
In this study, we revealed that amyloid burden acceler-
ated tau propagation in AppNL-G-F mice compared to
WT mice and depleting microglia dramatically reduced
tau propagation to the GCL. Additionally, increased de-
position of NP tau as well as amyloid plaques following
microglia depletion in AppNL-G-F mice suggested active
clearance of protein aggregates by MGnD microglia.
Interestingly, we observed that Clec7A+ MGnD micro-
glia, activated in response to amyloid plaques and p-tau
strongly expressed an exosomal marker, Tumor suscep-
tibility gene 101, which was absent after microglia deple-
tion. We further constructed a novel lentivirus
expressing mEmerald-CD9 fusion protein (mE-CD9) in
a microglia-specific manner and quantified the release of
mE-CD9+ EV particles from single cells in vivo in the
MEC. We found that the degree of EV release was over
three times highe from Mac2+ MGnD microglia com-
pared to Mac2− microglia. Additionally, co-injection of
mE-CD9 and AAV-P301L-tau revealed incorporation of
p-tau within microglia-specific EVs. MGnD microglia,
which are more prevalent in AppNL-G-F, appeared to re-
lease 3–5 times more p-tau through EVs compared to
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homeostatic microglia. These data highlight a possible
mechanism for the accelerated tau propagation wit-
nessed in AppNL-G-F mice via MGnD microglia-derived
EVs and may shed light on the conflicting microglial
roles in AD pathology development and progression.
Results
Microglia depletion increases plaque deposition
Immunofluorescence against IBA1, a marker for
microglia and macrophages [25], showed that IBA1
was almost completely absent (> 93%) after 2 months
of drug treatment in both groups (Fig. 1a-c). Add-
itionally, overall P2RY12+ area is not statistically dif-
ferent between WT and AppNL-G-F mice, which is also
depleted by PLX5622 (Fig. S1A-B). In the AD brain,
microglia become activated in response to amyloid
pathology and migrate to the region where they com-
pact and phagocytose Aβ plaques [26–29]. We hy-
pothesized that microglia depletion altered the Aβ
plaque compaction in AppNL-G-F mice. Staining with
thioflavin-S revealed the circularity of dense-core pla-
ques was significantly reduced following microglia de-
pletion, suggesting that Aβ plaques were less
compacted in the absence of microglia (Fig. 1d-e).
Consistent with this data, overall Aβ plaque area,
number, and size were significantly increased by
microglia depletion (Fig. 1e). 3D surface renderings of
thioflavin-S plaques revealed a dramatic decrease in
sphericity and increase of plaque volume and area
(Fig. S1C-D). These findings were mostly reproduced
in diffuse amyloid staining with 4G8 (detecting
Aβ17–24, Fig. 1f-g), specifically in the size of plaques
and overall plaque area. Interestingly, immunofluores-
cence for diffuse amyloid with an alternative antibody,
82E1, revealed no differences in plaque pathology
after microglia depletion in the same brains (Fig. 1h-
i). Moreover, 82E1 possessed a distinct staining pat-
tern from 4G8 (Fig. S1E). The 82E1 antibody detects
Aβ1–16, which is analogous to the 6E10 antibody,
most commonly used in studies assessing the effect of
microglia depletion on amyloid burden (Supplemen-
tary Table S1). The discrepancy in the Aβ plaque de-
tection between 82E1 and 4G8 antibodies may be an
important consideration for future studies. In
addition, immunofluorescence against the astrocytic
marker, Glial fibrillary acidic protein (GFAP) revealed
that microglia depletion had no impact on astrogliosis
in WT mice (Fig. S1F-G), confirming results from a
previous report [30]. Furthermore, there was a robust
increase in astrogliosis around Aβ plaques in
AppNL-G-F mice compared to WT mice that was un-
affected by PLX5622 treatment (Fig. S1F-G). Similarly,
a previous report indicated that microglia depletion
did not affect astrogliosis in response to tau pathology
[23]. Together, these results strongly suggest that
microglia play a significant role in prevalence of Aβ
plaques as well as their compaction in AppNL-G-F mice
between 4 to 6 months of age.
Enhanced tau propagation and its reduction by CSF1R
inhibition in AppNL-G-F mice
P-tau propagates from the MEC to the hippocampus,
which are anatomically-connected regions as seen in the
process of tau pathology development in AD. The per-
forant pathway projects from the MEC to the DG and
composes the tri-synaptic circuit together with mossy fi-
bers connecting to Cornu Ammonis 3 (CA3) and the
Schaffer collaterals to CA1 (Fig. 2a) [31]. To determine
the effect of microglia depletion on tau propagation via
the perforant pathway in AppNL-G-F mice, animals were
treated 1 month with PLX5622 or control chow from 4
months of age. AAV2/6 pseudotyped synapsin-1
promoter-driven transgene expression of P301L MAPT
mutant (AAV-P301L-tau) was injected into the MEC
(AP: 4.75, ML: 2.90, DV: 4.64) in AppNL-G-F and WT
mice at 5 months of age as previously described (Fig. 2a)
[22]. The animals were fed PLX5622 or control chow for
another month until the end point of the study (2
months treatment in total). Tau propagation from the
MEC to the DG was assessed by the immunofluores-
cence against p-tau (AT8, detecting pSer202/pSer205 tau).
Following injection of AAV-P301L-tau, we observed
strong AT8+ cell soma staining in the MEC and in the
GCL of the DG in AppNL-G-F mice and also in WT mice
to a lesser extent (Fig. 2b). Furthermore, we also found
AT8+ cells in the hilus and CA1 regions in both WT
and AppNL-G-F mice (Fig. S2A-B), suggesting that p-tau
was propagated through not only the perforant pathway,
but also possibly the temporoammonic pathway, which
projects from the EC layer II to CA1 [32]. These results
were consistent with previous reports showing an aug-
mented effect of amyloid plaques on tau propagation
[10, 12, 33]. Strikingly, microglia depletion effectively
suppressed the tau propagation in both groups (Fig. 2c),
and notably the inhibitory effect of microglia depletion
on tau propagation was more prominent in AppNL-G-F
compared to WT mice.
In addition to AT8+ neurons, neuritic plaque-
associated AT8+ tau deposits (NP tau) were investigated.
One recent study demonstrated the significant effect of
TREM2 mutation on NP tau formation in tau fibril-
injected APPPS1–21 mouse brains, suggesting microglial
involvement in NP tau development [13]. We thus
examined the effect of AAV-P301L-tau propagation on
NP tau formation in AppNL-G-F mice with or without
microglial depletion. Interestingly, AT8+ NP tau sur-
rounding plaques was increased following AAV-P301L-
tau incubation in the MEC, which was further
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significantly enhanced by microglia depletion (Fig. 2d-e).
In the hippocampus, proportions of NP tau showed simi-
lar patterns following injection and microglia depletion,
but were insignificantly different (Fig. S2C). This sug-
gests that tau expressed in the MEC can also spread and
be incorporated in NP tau, which may be actively phago-
cytosed by plaque-associated microglia. Together, these
data provide a strong evidence that Aβ deposition exac-
erbates tau propagation in a microglia dependent
manner.
Fig. 1 PLX5622 treatment ablates microglia and increases amyloid plaque burden. a. Schematic of study design with PLX5622 administration. The
table displays the number of mice used per experimental group. b. Representative images of IBA1 staining in the cortical region from WT and
AppNL-G-F mice administered with control (CTRL) or PLX5622 chow. c. Unbiased quantification of percentage IBA1+ area in the cortex. d.
Representative images of Thioflavin-S staining in the cortex. e. Unbiased quantification of plaque characteristics in Thioflavin-S stained slices in
the cortex. f. Representative images of 4G8 staining in the cortex. g. Unbiased quantification of plaque characteristics in 4G8 stained slices in the
cortex. h. Representative images of 82E1 staining in the cortex. i. Unbiased quantification of the plaque characteristics in 82E1 stained slices in
the cortex. Representative images displayed in a-i are a mix of male and female mice. All values displayed in a-i represent the mean ± standard
error (SEM) for a minimum of 6 animals per group. Graphs comparing values across all 4 groups were analyzed via 2-way analysis of variance
(ANOVA) with Tukey post-hoc analysis for individual comparisons. Graphs comparing two groups were analyzed via Unpaired t-test. *p < 0.05, **
p < 0.01, *** p < 0.001, between indicated groups. #### p < 0.0001 for the PLX5622 factor
Clayton et al. Molecular Neurodegeneration           (2021) 16:18 Page 4 of 16
Increased synaptic tagging and EV release signatures in
the amyloid bearing brain
C1q is a protein complex known to be a part of the
complement system and is also mostly derived from
microglia [34]. It is highly deposited on synapses in the
molecular layer of the DG [35, 36]. The expression level
of C1q in the outer molecular layer was significantly re-
duced in AppNL-G-F mice following microglia depletion,
revealing the absence of microglia-derived proteins
(Fig. 3a-b). There was no significant change in C1q
Fig. 2 Aβ deposition accelerates tau propagation in a microglia-dependent manner, while microglial depletion enhances NP tau formation. a.
Schematic of injection coordinate and tri-synaptic pathway. b. Representative images of AT8 staining in the MEC and the GCL region of the DG.
c. Unbiased quantification of AT8+ cell propagation from the MEC to the GCL. Tau propagation values across all 4 treatment groups are
displayed. d. Representative image of plaques in the MEC of non-injected AppNL-G-F mice, injected mice receiving control chow, and injected mice
receiving PLX5622. e. Unbiased quantification of percentage AT8+ plaque area within the MEC. Representative images displayed in a-e are a mix
of male and female mice. All values displayed in a-e represent the mean ± SEM. Graphs comparing values across 4 groups were analyzed via 2-
way ANOVA with Tukey post-hoc analysis for individual comparisons. Graphs comparing values across 3 groups were analyzed via 1-way ANOVA
with Fisher’s LSD post-hoc analysis for individual comparisons. * p < 0.05, ** p < 0.01 between indicated groups
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positivity in WT mice by microglia depletion and C1q
knockout mice showed no positivity as a negative con-
trol. In the AD brain, microglia become activated in re-
sponse to amyloid pathology and migrate to compact
and phagocytose plaque material [26–29]. We next ex-
amined MGnD microglia in the OML and specifically
around plaque regions in AppNL-G-F mouse brains via
Clec7A staining [8]. Clec7A+ MGnD microglia were de-
tected concentrated around plaques and were ~ 80%
eliminated following PLX5622 treatment in AppNL-G-F
mice (Fig. 3c-d). Microglia are known to produce and
secrete EVs more efficiently following activation [37].
We found striking co-expression of Tumor susceptibility
gene 101 (Tsg101), an EV marker in Clec7A+ MGnD
Fig. 3 Increased synaptic tagging and EV release signatures in the amyloid bearing brain. a. Representative images of C1Q, 4G8, and DAPI
staining in the hippocampal region of WT and AppNL-G-F mice administered with control (CTRL) or PLX5622 chow as well as C1Q KO mice. b.
Unbiased quantification of C1Q intensity in the OML of the hippocampus. c. Representative stacked confocal images of 4G8, Clec7A, and Tsg101
staining of plaques in the OML. See also Supplemental Fig. S3A and Video S1. d. Unbiased quantification of percentage Clec7A+ area across the
OML for all groups and of the plaque-specific regions. e. Unbiased quantification of Tsg101 intensity of plaque-positive regions in the OML
compared to background signal. f. qPCR data displaying fold-increases in MGnD and EV-associated markers ApoE, C1Qa, CD9, CD81, CD63,
Tsg101, and P2RY12 expressed in Clec7A+ over Clec7A− microglia. Representative images displayed in a-f are a mix of male and female mice. All
values displayed in a-f represent the mean ± SEM for a minimum of 3 animals per group. Graphs comparing values across all 4 groups were
analyzed via 2-way ANOVA with Tukey post-hoc analysis for individual comparisons. Graphs comparing two groups were analyzed via Unpaired t-
test. * p < 0.05, ** p < 0.01, and *** p < 0.001 between indicated groups. ## p < 0.01 for the PLX5622 factor
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microglia, which was also diminished by PLX5622 treat-
ment (Fig. 3c, e, Supplemental Video S1). This suggests
that MGnD microglia may be over-synthesizing EVs.
Homeostatic microglia, indicated by IBA1+/Clec7A−
cells, do not colocalize with Tsg101 (Fig. S3A). Addition-
ally, Clec7A+/− microglia were isolated from 6-month-
old AppNL-G-F mice via fluorescence-activated cell sort-
ing (FACS) via staining for CD11b, FCLRS, and Clec7A
(Fig. S3B). Clec7A+ microglia show significantly upregu-
lated gene expression of EV markers, such as Cd9 and
Cd63, along with MGnD marker ApoE compared to
Clec7A− microglia (Fig. 3f). Additionally, expression of
P2RY12 was not affected by the MGnD phenotype.
Lastly, plaque-associated Clec7A+ MGnD microglia ap-
pear to internalize NP tau (Fig. S3C and Video S2),
which supports our hypothesis that MGnD microglia
may actively phagocytose NP tau and dystrophic neurites
near the plaques. Together, these findings suggest that
MGnD microglia phagocytose NP tau and hyper-secrete
EVs, which may influence the spread of pathologic tau
seeds.
To directly determine if MGnD microglia release more
EVs compared to homeostatic microglia in vivo, we de-
veloped a novel microglia-specific lentivirus expressing
mEmerald-CD9 (mE-CD9) fusion protein (Fig. 4a) [38].
This lentivirus contains the tandem miR-9 target se-
quence (miR9T) on the 3’UTR, which is targeted by
miR-9-expressing neuronal cells and ensures silencing of
gene expression in any non-microglial cells [39] and
therefore achieving microglia-specific expression of mE-
CD9. We also incorporated the EF1α promoter, which is
highly active in murine microglia [40]. In vitro transduc-
tion of HEK293T cells demonstrates transgene expres-
sion within 48 h (Fig. S4A). mE-CD9 was enriched in the
EV fraction of the conditioned media compared to the
cell lysate (Fig. S4B). The high-titer (~ 1 × 109 TU/mL)
mE-CD9 lentivirus was bilaterally injected into the MEC
of both WT and AppNL-G-F mice at 6 months of age.
Following 10-day incubation, microglia-specific
expression of mE-CD9 was detected by GFP antibody
staining (Fig. 4b). MGnD microglia, which are indicated
by Mac2 staining positivity, were observed as mE-CD9+
plaque-associated microglia in AppNL-G-F brains (indi-
cated by white arrows), and were absent in WT brains
lacking AAV-P301L-tau injection. Triple immunofluor-
escence staining of mE-CD9, IBA1 and P2RY12 showed
that ~ 94% of mE-CD9+ signal co-localized with these
microglia markers (Fig. S4C), indicating microglia-
specific expression of mE-CD9. MGnD were detected by
Mac2 staining [41], which coincide with Clec7A+ MGnD
nearly 100% of the time (Fig. S4D), suggesting that both
antibodies detect the same population of MGnD micro-
glia. Z-stack images of mE-CD9+/Mac2− microglia in
WT mice, and mE-CD9+/Mac2± microglia in AppNL-G-F
mice were captured via Leica SP8 with Lightning super-
resolution confocal microscope and processed in IMAR
IS rendering software to automatically quantify the num-
ber of mE-CD9+ EV particles (white voxels) surrounding
individual microglia (Fig. 4c). Quantification of mE-
CD9+ EV particles localized around individual microglia
revealed that Mac2+ MGnD microglia released over 3
times as many EVs as Mac2− microglia (Fig. 4d). The in-
tensity of Mac2 staining in microglia showed a strong
positive correlation with the particle number of EVs,
suggesting that the MGnD phenotype positively influ-
enced EV release (Fig. 4e). We then isolated the EVs
from the left hemisphere of the bilaterally-injected
brains using discontinuous sucrose gradient ultracentri-
fugation method as previously described [42, 43]. Bio-
chemical quantification of mE-CD9 was performed
using whole brain homogenate and extracellular vesicles
isolated from mE-CD9 lentivirus-injected brains by GFP
ELISA, which cross-react with mEmerald (Fig. S4E).
There was significant enrichment of mE-CD9 in the EV
fraction over brain homogenate both in WT and
AppNL-G-F mice, biochemically confirming the secretion
of mE-CD9+ EVs in vivo. Taken together, these data
demonstrate that MGnD microglia, elicited here by Aβ
plaques, secrete significantly more EVs than non-MGnD
microglia in AppNL-G-F mice in vivo.
P-tau is encapsulated within microglia-specific EVs, which
is augmented in MGnD microglia
If the hypersecretion of EVs by MGnD microglia is in-
volved in the seeding and propagation of pathologic tau
between brain regions, we should be able to observe p-
tau encapsulated by microglia-derived EVs. In order to
investigate this possibility, we bilaterally injected mE-
CD9 lentivirus into the MEC of 4-month-old WT and
AppNL-G-F mice followed by the injection of AAV-
P301L-tau in the same region one month later (Fig. 5a).
Mice were euthanized at 6 months of age. Immunofluor-
escence staining for GFP in order to detect mE-CD9 and
AT8 for p-tau labeling indicated successful co-
expression of mE-CD9 lentivirus and AAV-P301L-tau in
the same region (Fig. 5b). MGnD microglia, indicated by
Mac2+ microglia, were elicited in response to AAV-
P301L-tau injection in both mice, but were significantly
more prevalent in AppNL-G-F mice compared to WT con-
trol mice (Fig. S5A). Confocal z-stack images of
individual p-tau associated microglia demonstrated that
there were both homeostatic microglia and MGnD
microglia in the p-tau-expressing region in either group
(Fig. 5c). As seen before, these microglia appeared to be
surrounded by mE-CD9+ EVs. Renderings of high-
magnification images revealed that p-tau was encapsu-
lated by microglia-specific EVs around homeostatic
microglia and MGnD microglia in the tau-injected brain
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region (Fig. 5d and Video S3). EVs were isolated from
co-injected brains as described before and subjected to
double immuno-gold labeling of AT8 to detect p-tau (5
nm immuno-gold dot) and GFP to detect membrane-
localized mE-CD9 (10 nm immuno-gold dot). Immuno-
electron microscopic captured images of EVs revealed
the presence of AT8+ p-tau encapsulated by GFP+
microglia-specific EVs (Fig. 5e). EVs surrounding Mac2−
and Mac2+ microglia were quantified as done previously
(n = 8 microglia per group). MGnD microglia secreted
roughly three times as many as EVs as homeostatic
microglia (Fig. 5f). Additionally, the amount of p-tau in-
ternalized by these microglia and their EVs was quanti-
fied (Fig. 5g-h). Regardless of whether in WT or
AppNL-G-F mice brains, Mac2+ MGnD microglia signifi-
cantly internalized and secreted p-tau+ mE-CD9+ EVs
Fig. 4 In vivo imaging of EV secretion from microglia after lentiviral microglia-specific expression of mE-CD9. a. Schematic of mE-CD9 lentiviral
construct. b. Representative images of mE-CD9 lentivirus transduction in WT and AppNL-G-F microglia following injection and 10-day incubation. c.
Representative images of individual microglia and released mE-CD9+ particles showing FSB, Mac2, and mE-CD9. d. Unbiased quantification of mE-
CD9+ voxels surrounding individual microglia (n = 12 microglia per group from 3 mice per group). e. Regression plot of Mac2 staining intensity
versus the number of mE-CD9 particles released by individual microglia. Representative images displayed in a-e are a mix of male and female
mice. All values displayed in a-e represent the mean ± SEM for a minimum of 3 animals per group. Graphs comparing values across all 4 groups
were analyzed via 2-way ANOVA with Tukey post-hoc analysis for individual comparisons. Graphs comparing two groups were analyzed via
unpaired t-test. ** p < 0.01, *** p < 0.001, between indicated groups
Clayton et al. Molecular Neurodegeneration           (2021) 16:18 Page 8 of 16
more than Mac2− homeostatic microglia. These data
suggest that microglia-derived EVs distribute pathologic
tau seeds, a phenomenon that is enhanced by the pheno-
typic shift of microglia into MGnD phenotype.
Discussion
Microglia depletion and tauopathy
The role of microglia in mediating the interplay between
amyloid and tau pathologies remains elusive. In the
Fig. 5 Pathologic tau is secreted through microglia-derived EVs. a: The timeline of injection of mE-CD9 lentivirus and AAV-P301L-tau. b:
Representative low-magnification images of the injection site in the MEC showing FSB (blue: amyloid plaque), mE-CD9 (green), Mac2 (red), and
AT8 (magenta). c: Left: Representative images of homeostatic microglia (Mac2−) and MGnD (Mac2+) with phagocytosed AT8+ p-tau and secreted
mE-CD9+ EVs (white) surrounding microglia. Right: Surface rendering images by IMARIS software showing internalized p-tau within microglia or
EVs. d: Representative images of microglia-derived mE-CD9+ EVs (white) containing p-tau (magenta). See also Supplementary Video S3. e:
Immuno-gold electron microscopy images of microglia-derived EV containing mE-CD9 fusion protein (GFP+ 10 nm immuno-gold dots) and p-tau
(AT8+ 5 nm immuno-gold dots). f: Quantification of mE-CD9+ EVs released from homeostatic microglia (Mac2−) and MGnD (Mac2+) in the injected
region. g: Volume of phagocytosed p-tau per microglia h: Quantification of total p-tau released through mE-CD9+ EVs per microglia.
Representative images displayed in a-h are a mix of male and female mice. f-h: n = 8 microglia per group from 5 WT and 5 AppNL-G-F animals.
Graphs comparing values across all 4 groups were analyzed via 2-way analysis of variance (ANOVA) with Tukey post-hoc analysis for individual
comparisons. * p < 0.05 between indicated groups, # p < 0.05, ## p < 0.01 for the Mac2 factor
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current study, we demonstrated that abnormally phos-
phorylated and aggregated tau propagates from the MEC
to the DG in WT and AppNL-G-F mice in a microglia-
dependent manner. We further provided evidence that
the neurodegenerative microglia phenotype MGnD pro-
duce and secrete abundant EVs containing p-tau, indi-
cating a novel mechanism for how activated microglia
may facilitate development and propagation of tau path-
ology. We previously reported the beneficial effects of
microglia depletion as well as inhibition of EV synthesis
and secretion in preventing tau spread in WT and
P301S tau transgenic mice [22, 44]. We witnessed the
same, but even more beneficial effect of microglia deple-
tion in a mouse model exhibiting the other pathological
hallmark of AD, Aβ plaques. Several studies including
ours demonstrate the beneficial effect of CSF1R
inhibitor-mediated microglia depletion on halting tauo-
pathy in different tau mouse models [22, 30, 45]. This
includes the AAV-mediated tau propagation system and
P301S mice, but not in hTau mice expressing human
wildtype tau or aged rTg4510 P301L tau mice, in which
only partial microglial depletion was achieved (Supple-
mentary Table S2) [23, 46]. One CSF1R inhibitor, JNJ-
40346527, was successful in suppressing tauopathy de-
velopment in P301S tau mice and is being tested in a
Phase 1 study of AD cases (NCT04121208).
In this study, we utilized the AppNL-G-F mouse model
and CSF1R inhibitor PLX5622 to determine the effect of
MGnD microglia on tau pathology development. It was
noted previously that at lower doses of PLX5622 treat-
ment, plaque-associated MGnD microglia are specifically
depleted whereas homeostatic microglia are extant [19].
In our study, treatment of mice with 1200 mg/kg
PLX5622 resulted in ~ 93% reduction in the amount of
microglia and ~ 80% of MGnD microglia. We note that
MGnD microglia are conventionally regarded as acti-
vated by Aβ plaques, but seemingly can also become ac-
tivated in response to AAV-P301L-tau injection as
evaluated by MGnD markers, Clec7A and Mac2.
Whether or not MGnD microglia elicited from these
two pathologies are phenotypically different remains to
be investigated in future studies.
Microglia depletion and amyloid plaques
Microglia may play bidirectional roles for Aβ clearance
via phagocytosis, endolysosomal clearance, and seeding
of Aβ aggregates depending on the age of animals and
the stage of Aβ accumulation in the brain. The general
consensus of previous research regarding the effect of
microglia depletion on amyloid deposition is that it is
largely ineffectual aside from those utilizing the 5xFAD
mouse model, which report dramatic improvements
of Aβ pathology following microglia depletion [20, 47–
49]. Here we found that microglia depletion causes a
sizeable increase in compact, but not diffuse amyloid de-
position (Supplemental Table S1). There are several pos-
sibilities which may explain the discrepancy between
ours and the previous findings. Firstly, all of the previous
studies assessing the effect of microglia depletion on
amyloid deposition used transgenic models that overex-
press human APP mutants (Supplementary Table S1).
Deposition as a result of overexpression in combination
with mutation may likely be more intense than the
AppNL-G-F model, which replaces the intrinsic mAPP
gene with the human version expressing three mutations
to increase amyloid deposition [24]. Therefore, depletion
of microglia in the former case may not have as large an
effect on amyloid deposition as in the latter; overexpres-
sion of APP may saturate the ability of microglia to clear
Aβ, resulting in no effect of depletion. Furthermore, the
heterogeneity of mouse models, onset, duration and effi-
ciency of microglia depletion, and techniques for quanti-
fying deposition all make comparisons difficult to
interpret. Among them, only two reports from Spangen-
berg et al. [20, 21] and this study show achievement of
at least 95% depletion of microglia and duration of at
least 2 months.
These studies revealed a reduction in plaque size and
number when microglia are depleted at a young age (1.5
months), suggesting that microglia may play a patho-
logical role in the early stage of Aβ deposition. Most
studies in which amyloid burden is assessed utilize 6E10
for staining, which recognizes residues 1–16 of Aβ. In
this study, we find no effect of microglia depletion on
amyloid deposition using the 82E1 monoclonal antibody,
which recognizes the same residues. However, staining
with 4G8, which recognizes residues 17–24 of Aβ, re-
vealed a dramatic increase in diffuse plaque deposition
that recapitulated the increases found in compact plaque
deposition determined by thioflavin-S staining. We sus-
pect the difference in plaque compaction is most visible
through thioflavin-S staining compared to diffuse plaque
staining possibly because diffuse portions of plaques are
not rigid and fibrillar enough for microglia to interact
with easily, and therefore not much difference is ob-
served here. Future studies to investigate the impact of
microglia depletion on Aβ should use a variety of
markers and techniques to uncover results. Data pre-
sented here suggest that microglia are indeed highly in-
volved in plaque compaction and clearance.
Microglial depletion and NP tau
In this study, overexpression of mutant P301L-tau in the
MEC of AppNL-G-F mice produced two different kinds of
tau pathology: increased AT8+ neurons at the GCL and
NP tau on amyloid plaques. Aggregated and phosphory-
lated tau in dystrophic neurites, recently described as
NP tau, is a known pathological hallmark of AD brains
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[10, 13]. We observed an increase in NP tau accumula-
tion by over-expressing P301L-tau mutation in the MEC
of AppNL-G-F mice. This is supported by a recent study
showing that tau fibril injection in AppNL-F mice induced
NP tau accumulation [10]. We found that microglia de-
pletion increased NP tau accumulation. Loss of Aβ com-
paction after microglial depletion could facilitate a larger
volume of Aβ fibril-induced dystrophic neurites. This is
consistent with the recent report demonstrating en-
hanced NP tau formation in APPPS1–12 mice with
TREM2 knockout or R47H mutant background, which
showed a diminished number of plaque-associated
microglia [13]. Authors speculated that microglial dys-
function increases the susceptibility of dystrophic neur-
ites to develop this pathology, possibly through
increased vulnerability to the toxic effects of Aβ42 in
plaques and not due to the reduction of the phagocytosis
activity of plaque-associated microglia. Here, our results
showing p-tau entrapped by plaque-associated MGnD
microglia provide an additional interpretation: NP tau
may be actively phagocytosed by plaque-associated
MGnD and their depletion allows for greater accumula-
tion of NP tau pathology. Thus, we speculate that
phagocytosed NP tau may also be an important source
for microglia to secrete tau seed-containing EVs.
MGnD microglia-derived EVs and tau propagation
In addition to the new possibility of NP tau-mediated
spread of tau pathology, microglia also phagocytose tau-
containing synapses. It is well known that microglia ac-
tively phagocytose synapses by synaptic tagging with com-
plements (C1q and C3) [50–52], which also play an
important role in Aβ-induced synaptic loss [53]. As shown
in the current and previous studies [36, 54], C1q signal is
highly intense in the OML, and this study shows that it is
microglia-dependent. C1q is likely to play a role in engulf-
ing damaged synapses containing pathological tau seeds
by microglia in the OML. Given that microglia are known
to be activated and recruited to the plaque region where
they surround, phagocytose, and also secrete toxic aggre-
gates through their EVs, we hypothesize that the activity
of plaque-associated MGnD microglia in this region may
inadvertently bolster tau propagation from the MEC to
the DG in AppNL-G-F mice (Fig. 6). Indeed, microglia-
derived EVs are endocytosed by proximal neurons and in-
fluence their activity [55–57]. Another recent report
showed that microglia isolated from AD brains or tau
mice can seed tau in vitro [58]. We developed a way to
measure EV release specifically from microglia in vivo
using the mE-CD9 lentivirus. This allowed us to quantify
the number of mE-CD9+ particles localized around in-
fected microglia using super-resolution microscopy. We
found that EV release was over three-times higher from
MGnD microglia compared to homeostatic microglia.
These data are supported by previous evidence showing
that many EV markers, such as CD63, CD9, CD81, and
Tsg101 are upregulated in MGnD microglia isolated from
APP or APP/PS1 mice [8, 59]. We recapitulated this find-
ing via qPCR using isolated Clec7A+/− microglia and by
immunofluorescence showing co-localization of Tsg101
and Clec7A in MGnD microglia around Aβ plaques in this
study. We utilized the mE-CD9 lentivirus and AAV-
P301L-tau to directly examine the interaction of mE-
CD9+ microglia with p-tau+ neurons, which also induced
MGnD microglia and appear to hyper-secrete EVs. Im-
portantly, mE-CD9+ EVs contained p-tau, suggesting that
microglia-derived EVs have the potential to seed p-tau ag-
gregates in neighboring or distant cells, exacerbating tau
propagation.
In summary, we provide strong evidence that MGnD
microglia release dramatically higher levels of EVs in re-
sponse to amyloid and tau pathology compared to inac-
tivated microglia. Additionally, these EVs appear to
contain pathologic p-tau, suggesting a potential mechan-
ism explaining how Aβ plaques enhance propagation of
tau pathology. It is possible that microglia depletion can
alleviate the propagation of pathologic tau through
alternative mechanisms, such as preventing microglia-
mediated activation of tau kinases through inflamma-
somes [60–63]. Therefore, in order to specifically test
the role of microglia-derived EVs in tau pathology
propagation, future studies involving microglia-specific
ablation of EV secretion are necessary.
Methods
Animals and genotyping
All mouse care and experimental procedures were ap-
proved by Institutional Animal Care and Use Committee
of the Boston University School of Medicine. AppNL-G-F
mice were bred and genotyped in-house. C57BL/6 were
purchased from the NIA. Mice were caged in accordance
with their own sex and housed in a barrier facility with
12 h light and 12 h dark cycles. Roughly half of the ani-
mals used were male and half female between WT and
AppNL-G-F groups. Food and water was provided ad libi-
tum. Throughout the life of all mice, veterinary staff
closely monitored animals for complications. Genotyp-
ing for animals was conducted in house via PCR using
the following primers [24]: E16WT: 5′ – ATCTCGGA
AGTGAAGATG – 3′ E16MT: ATCTCGGAAGTGAA
TCTA WT: 5′ – TGTAGATGAGAACTTAAC – 3′
loxP: 5′ – CGTATAATGTATGCTATACGAAG – 3′.
C1Q KO mice were obtained in good condition from
Jackson Laboratories (Stock No: 031675).
Viral vector production
The AAV2/6-SYN1-P301L tau (AAV-P301L-tau) was
generated as previously described [22]. This virus is
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recombinant AAV2/6 (AAV2/6) pseudoserotype, and
was created at Viral Core Facility, Boston Children’s
Hospital. The vector consists of AAV-2 inverted ter-
minal repeats, the human synapsin-1 gene promoter
driving expression of human P301L tau 1–441, the
woodchuck hepatitis virus post-transcriptional control
element (WPRE) and a bovine growth hormone polyade-
nylation site. Iodixanol step gradient ultracentrifugation
followed by heparin FPLC affinity chromatography and
dialysis in PBS overnight was used to purify and prepare
AAV particles. Viral titers were calculated via q-PCR.
Purity of AAV was determined by SDS-PAGE and Coo-
massie brilliant blue staining.
CSF1R inhibitor treatment and intracranial injection
PLX5622 or control (Plexxikon, Inc., San Francisco, CA),
was impregnated into rodent chow at 1200 ppm (AIN-
76A, Research Diet, Inc., Brunswick, NJ) and provided
the animals in equal quantity starting at 4 months of
age. After one month since the beginning of PLX5622
treatment, intracranial injections of AAV-P301L-tau
were administered to the control- and drug-treated
mice. This AAV expresses the mutant version of human
tau P301L under the syn-1 promoter, which is neuron-
specific [64]. Nine tenths of 1 μL were injected into each
mouse with coordinates (AP: 4.75, ML: 2.90, DV: 4.64)
at a viral titer of 1.2 × 1011 using a robotic stereotaxic
drill & microinjection machine (Neurostar, Tubingen,
Germany) attached with 10-μl syringe (Hamilton, model
701 LT, #80301) and glass capillary (Neurostar) held to-
gether with microelectrode holder (World Precision In-
struments #MPH6S10). Mice were anesthetized during
the procedure with 3% isoflurane and received 1 mg/kg
meloxicam for pain relief. Experimenters were blinded
Fig. 6 Schematic diagram of Aβ plaque deposition and microglia-mediated tau propagation. In the WT mouse brain, tau propagation from the
MEC to GCL neurons is sensitive to microglia. In AppNL-G-F mouse brains, Aβ plaque associated microglia are more phagocytic and hyper-secrete
tau-seeding EVs compared to homeostatic microglia, resulting in enhanced tau propagation from MEC to GCL regions. Both Aβ plaque and NP
tau pathology are increased following microglia depletion, suggesting their active roles on compaction and clearance of Aβ plaques and NP tau
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to which group received PLX5622 and which received
placebo throughout the experiment. Animals experien-
cing undue trauma or distress following injections were
sacrificed and excluded from the study. Following one-
month incubation of virus with continuous PLX5622
treatment, animals were sacrificed via transcardial perfu-
sion with PBS and followed with fixation by 4% parafor-
maldehyde (PFA) solution. Brains were immediately
harvested.
Histological processing and immunofluorescence staining
Brains were immersed in 4% PFA at 4C° for overnight
following harvest. The following day, brains were placed
in 30% sucrose solution in PBS in 4C° for overnight
again in preparation for cryosectioning. Sagittal brain
slices were then gathered using a Cryostar NX50
(Thermo Fisher Scientific, # 957250 K) at 30 μm thick-
ness. Following sectioning, brains were mounted on
superfrost plus microscope slides (Thermo Fisher
Scientific, #22–037-246) and stored at − 80 °C. The fol-
lowing antibodies and reagents were used for immuno-
fluorescence staining: 4G8 1:100 (Aβ17–24, BioLegend,
#800704), AT8 1:300 (pSer202/pSer205 tau, Thermo,
#MN1000), GFAP 1:300 (Cell Signaling Bio, #36705),
C1q 1:300 (Abcam, #ab182451), 82E1 1:100 (Aβ1–16,
IBL, #10323), thioflavin-S 1:50 in 50% ethanol (Sigma,
#T1892-25G), 1-Fluoro-2,5-bis[(E)-3-carboxy-4-hydro-
xystyryl] benzene (FSB, 50 μM) in 10% ethanol (Milli-
pore Sigma, #07602), HT7 1:300 (human tau, Thermo,
#MN1000), Clec7A 1:100 (InvivoGen, #mabg-mdect),
Tsg101 1:300 (Santa Cruz Biotech, #sc-7964), IBA1
(Wako, #019–19,741), DAPI 1:2500 (Thermo Fisher
Scientific, #62248). Rabbit polyclonal anti-mouse
P2RY12 antibody 1:600 was generously provided by Dr.
Oleg Butovsky’s laboratory [65, 66]. Sections were
washed with PBS prior to antigen retrieval with 88% for-
mic acid except for staining with anti-GFP antibody
(Santa Cruz Biotech, #sc-101,536). Blocking solution
consisted of 5% normal goat or donkey serum, 5% bo-
vine serum albumin (BSA), and 1% Triton X-100. All
following primary and secondary staining buffer con-
sisted of 5% BSA, 1% Triton X-100 in PBS. Following
staining, sections were allowed to air-dry and then
mounted using Fluoromount-G (Invitrogen, #00–4958-
02). Tiled images were taken at 20X with an Eclipse Ti
microscope (Nikon Instruments). Confocal images were
taken using SP8 laser confocal microscope with
Lightning (Leica). Images were observed and analyzed
using open-source image processing package FIJI.
Processing of z-stack images and quantification of mE-
CD9+ particles was accomplished using IMARIS
rendering software (Oxford Instruments). The face of
each z-stack is 50-μm by 50-μm and the thickness is ap-
proximately 30 μm.
Microglia isolation and sorting
Mice were transcardially perfused with ice-cold Hanks
Balanced Salt Solution (HBSS) and whole brains were re-
moved. Brain tissue was dissected into 1-mm3 pieces
and homogenized into a single cell solution in ice cold
HBSS using a glass Dounce homogenizer. Single cell sus-
pensions were centrifuged over a 37%/70% discontinu-
ous Percoll (GE Healthcare) gradient. Mononuclear cells
were isolated from the interphase of these layers. In
order to distinguish resident microglia from recruited
myeloid cells, we used a monoclonal antibody that rec-
ognizes FCRLS, which is expressed on microglia, but not
infiltrating myeloid cells [8, 65]. Isolated cells were
stained with anti-FCRLS-APC, along with CD11b-
PeCy7, Ly6C-PercpCy5.5, LIVE/DEAD Blue Dead Cell
Stain for UV Excitation, followed by rat primary anti-
body against Clec7A (1:100) (InvivoGen) and secondary
anti-rat FITC. Doublets were removed and the LIVE/
DEADLO CD11bHI Ly6CLO FCRLS+ Clec7A+/− microglia
populations were isolated.
RNA isolation, cDNA synthesis, and quantitative PCR
For purification of microRNA and total RNA from iso-
lated microglia, the miRNeasy Mini Kit was used accord-
ing to manufacturer protocols (Qiagen, #217004). cDNA
synthesis was achieved using the Superscript VILO
cDNA synthesis kit (Thermo Fisher Scientific
#11754050) with an initial RNA input of 100 ng after
DNase I digestion (Ambion, # AM2222). Quantitative
PCR was carried out in 6 μL total volume. Each reaction
volume consisted of 0.5 μL of primers (Thermo Fischer
Scientific, # 4331182), 1.5 μL of cDNA, 3 μL of water,
and 1 μL of Taqman Fast Advanced Master Mix
(Thermo Fisher Scientific, #4444557). The amplification
was conducted using an ABI Prism 7900HT Sequence
Detection System.
Lentiviral vector production
The pLV-EF1α-mEmerald-CD9-miR9T lentivirus was
generated by modifying commercially available
pLV.PGK.GFP.miR9T lentivirus [39]. The vector back-
bone was modified to contain the murine EF1α pro-
moter and express mEmerald conjugated to CD9
followed by miR9T in the 3’UTR. mEmerald-CD9–10
was a gift from Michael Davidson (Addgene plasmid #
54029; http://n2t.net/addgene:54029; RRID:Addgene_54,
029). Viral particle production and packaging was done
by a commercial source (SignaGen Laboratories,
Rockville MD, USA). The viral titer is >1E + 9 TU/ml.
Lentivirus (1 μL) was injected to the MEC (AP: 4.75,
ML: 2.90, DV: 4.64) of 6 months-old AppNL-G-F and WT
mice and euthanized at 10-day post-injection for immu-
nohistochemical and biochemical analyses.
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Cell culture transduction
Human embryonic kidney 293 T (HEK293T) cells were
cultured in 24-well tissue culture-treated plates with 1%
penicillin-streptomycin (Thermo Fischer Scientific,
#15140122), 10% fetal bovine serum (FBS, Thermo Fi-
scher Scientific, #A3382001) in Dulbecco’s Modified
Eagle Medium (DMEM, Invitrogen #11965118) for 24 h
prior to plasmid DNA transduction. HEK293T cells were
serum-starved for 1 h in DMEM prior to receiving 1 μL
of mE-CD9 lentivirus or control lentivirus.
Immunoblotting
Transfection was performed with pLV-EF1α-GFP-
miR9T or pLV-EF1α-mEmerald-CD9-miR9T plasmid
(2.5 μg/well) using Lipofectamine 3000 (Thermo Fisher
Science, #L3000008). Whole cells and conditioned
medium were collected 3 d after transfection. The condi-
tioned medium was centrifuged at 2000 g for 30 min, at
10,000 g for 30 min, at 144,000 g for 70 min and last pel-
lets were collected as the EV fraction. Whole cells or EV
fractions were lysed with RIPA buffer containing Halt
Protease and Phosphatase inhibitor Cocktail (Thermo
Fisher Science, #78442), and incubated at 95 °C for 5
min with Laemmli sampling buffer (Bio-Rad, #S3401-
10VL) supplemented with 2% v/v 2-mercaptoethanol.
The protein samples (10 μg/lane) were subjected to 10%
SDS-PAGE, transferred to PDVF membrane (Bio-Rad),
and blocked with 3% skim milk in TBS 0.5% Tween20
(TBS-T). The membranes were incubated overnight at
4 °C with anti-GFP mouse monoclonal antibody (Santa
Cruz Biotech, B-2; 1:500), and washed with TBS-T. Then
the membranes were incubated with HRP-conjugated
anti-mouse IgG antibody (Cell Signaling Technology,
#7076; 1:10,000) for 1 h at room temperature. The pro-
teins were detected with Immobilon chemiluminescent
HRP substrate (Millipore Sigma, #WBKLS0100) and vi-
sualized with Chemiluminescent Western Blot Imaging
System (Azure, #C300).
Purification of EVs
Following sacrifice and transcardial perfusion with cold
PBS, mouse brains were cut in half sagittally and the left
half was used for EV purification. Left hemispheres were
sliced with a razor into thin strips > 1mm in width and
subjected to digestion in 1.5 mL of collagenase diluted
into Hibernate E (Invitrogen, #A1247601) (75 U/mL)
(Worthington Biochemical, #LS004180) at 37 degrees
Celsius for 15 min with occasional stirring. Next, prote-
ase inhibitor was added at the recommended dilution
(Thermo Fisher, #P178443) and the brains were mech-
anically homogenized for approximately 2 min and then
subjected to 40-μm filtration (Fisher Scientific, #22–363-
547). Solutions were then processed by sequential centri-
fugation in the following order and the supernatant was
used for the next step each time: 300 g for 10 min, 2000
g for 10 min, and 10,000 g for 10 min. Solutions were
then filtered through 0.22-μm filters and subjected to
ultracentrifugation at 140,000 g for 70 min. Lastly, pellets
were subjected to sucrose gradient and separated at 200,
000 g for 20 h. The 0.65M and 0.8M sucrose fractions
were pooled then diluted in 12ml of cold PBS and sub-
jected to ultracentrifugation at 140,000 g for 70 min.
Immunoelectron microscopy
The EV pellet was then fixed in 4% formaldehyde with
0.1% glutaraldehyde for 2 h at RT then washed with PBS
containing 20 mM glycine. Following fixation, the pellet
was processed for ultra-thin cryosectioning. The pellets
were infiltrated with 2.3 M sucrose in PBS for 15 min,
frozen in liquid nitrogen, and then sectioned 80-nm
thick at -120C° as previously described [22]. Sections
were transferred to a carbon-coated copper formvar grid
and labelling was conducted on a piece of parafilm.
Blocking with 1% BSA for 10 min was used to prevent
non-specific labelling. All antibodies were diluted in 1%
BSA in PBS. Labeling for p-tau was conducted using
AT8 1:30 (pSer202/pSer205 tau, Thermo Fisher Scien-
tific, #MN1000) for 30 min, followed by rabbit anti-
mouse bridging antibody (1:50, AbCam, ab6709) for 30
min and 5-nm protein A-gold (1:50, University Medical
Center, Utrecht, the Netherlands) for 20 min. After four
washes in PBS, the grids were fixed for 5 min in 1% glu-
taraldehyde in PBS, followed by four washes in 20mM
glycine in PBS (to quench free aldehyde groups).
mEmerald-CD9 was labelled using anti-GFP rabbit poly-
clonal antibody (AbCam ab6556; 1:30) followed by 10-
nm Protein A gold (1:50). This was followed by washing
with PBS and water for 15 min. Sections were then con-
trasted with 0.3% uranyl acetate in 2% methylcellulose
for 5 min. Grids were examined at 80 kV with a Tec-
naiG2 Spirit BioTWIN transmission electron micro-
scope. Images were recorded with an AMT 2 k CCD
camera.
Statistical analysis
All statistical analyses were performed in GraphPad
Prism 8 (Graph-Pad Software, Inc). Two-way ANOVA
was used to assess comparisons between all four experi-
mental groups when applicable. Normal distributions
were assumed when making post-hoc analyses and cor-
recting for multiple comparisons (Tukey). In instances
of two group comparisons, unpaired t-tests assuming
equal variances were used.
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